Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries.

Could patents interfere with the development of a cardiovascular polypill? J Transl Med (2016) 0.75

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2014) 26.76

A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 14.88

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet (2008) 11.56

The concept of access: definition and relationship to consumer satisfaction. Med Care (1981) 10.22

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet (2011) 5.95

Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82

Missing in action: teacher and health worker absence in developing countries. J Econ Perspect (2006) 4.47

Inequalities in non-communicable diseases and effective responses. Lancet (2013) 4.18

Hypertension in developing countries. Lancet (2012) 3.98

The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med (2012) 3.96

WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ (2005) 3.09

The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation (2014) 2.99

Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med (2013) 2.99

Access to medicines from a health system perspective. Health Policy Plan (2012) 2.39

Universal coverage of health services: tailoring its implementation. Bull World Health Organ (2008) 2.30

Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord (2010) 2.22

Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ (2011) 1.98

Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ (2012) 1.98

The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin Epidemiol (2011) 1.88

Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet (2013) 1.85

Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One (2014) 1.81

Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet (2015) 1.71

Impact of insurance and supply of health professionals on coverage of treatment for hypertension in Mexico: population based study. BMJ (2007) 1.60

Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2013) 1.59

The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation (2010) 1.51

Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev (2002) 1.22

The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med (2013) 1.20

Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health (2012) 1.15

Influence of tropical climate conditions on the quality of antihypertensive drugs from Rwandan pharmacies. Am J Trop Med Hyg (2009) 1.06

Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries. Health Policy Plan (2014) 1.05

Penicillin for rheumatic fever prophylaxis 3-weekly or 4-weekly schedule? J Assoc Physicians India (1987) 0.90

A simplified echocardiographic strategy for heart failure diagnosis and management within an integrated noncommunicable disease clinic at district hospital level for sub-Saharan Africa. JACC Heart Fail (2013) 0.88

Medicines availability for non-communicable diseases: the case for standardized monitoring. Global Health (2015) 0.80

Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines. Trop Med Int Health (2010) 0.80

Evaluating the quality and use of economic data in decisions about essential medicines. Bull World Health Organ (2015) 0.77

Descriptive epidemiology and short-term outcomes of heart failure hospitalisation in rural Haiti. Heart (2016) 0.76